Precipio: Ron Andrews
Precipio has announced that Ron Andrews has joined the company's board of directors. In addition to currently serving as CEO of molecular diagnostics firm OncoCyte, Andrews' past experiences include a term as CEO of Roche Molecular, president of the genetic science division at Thermo Fisher Scientific, president of the medical sciences venture at Life Technologies, and CEO of Clarient.
ERS Genomics: Jon Kratochvil
ERS Genomics has appointed Jon Kratochvil as vice president for business development and licensing for North America. Kratochvil previously served as director of business development and licensing at MilliporeSigma, where he was responsible for global development opportunities for the company's gene editing and novel modalities technologies. He has also previously served as business development director for Washington University, and as licensing manager and competitive intelligence analyst for Abbott Laboratories' diagnostics division.
Omniome: Thomas O'Lenic
Sequencing firm Omniome has appointed Thomas O'Lenic as chief commercial officer. O'Lenic previously held commercial, general manager, and executive leadership positions with Advanced Cell Diagnostics (now part of Bio-Techne); IntegenX (now part of Thermo Fisher Scientific); Molecular Devices (a Danaher company); PerSeptive Biosystems, Millipore, and FreeSlate.
PierianDx: Lindsay Mateo
PierianDx, which specializes in cancer informatics for diagnostics and targeted therapies, has appointed Lindsay Mateo as chief business officer. Mateo previously served as head of commercial operations and later as vice president and head of life sciences at Tempus. She has also led commercial teams at Navican, an Intermountain Healthcare Company; and Genoptix, now part of NeoGenomics.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.